Peptide Receptor Radionuclide Therapy (PRRT) Market is expanding as Soricimed Biopharma Inc. collaborates with Orano Med to develop a novel PRRT to treat solid tumor cancers

 

One of the most effective treatment options for patients with metastatic lung cancer is the use of peptide receptor iontophoresis. This procedure involves the injection of a small amount of a peptide, generally an amino acid or carboxylic acid, into the affected tissue where it stimulates a release of energy from the cells. One of the key factors that aid growth of the said market is growing cases of pancreatic neuroendocrine tumor and gastrointestinal tract neuroendocrine tumors. As per the American Cancer Society, in 2021, around 4,200 people in the U.S. are likely to be diagnosed with pancreatic neuroendocrine tumor (NET). Generally, people with pancreatic NETs are aged 60 years and above with the disease being most common in women. PRRT is a unique way to approach neuroendocrine tumors, which could benefit the patient. Hence, these factors can stimulate growth of the peptide receptor radionuclide therapy (PRRT) market.

Another key factor fueling growth of the market is continuous research and development activities to innovate novel treatment approach for cancer. Key companies are focused on R&D activities by collaborating with other international players and develop novel treatment options. Besides, rapid product approval by regulatory authorities could potentially accelerate growth of the peptide receptor radionuclide therapy (PRRT) market. Recently, in January 2021, Soricimed Biopharma Inc. collaborated with Orano Med to develop a novel peptide receptor radionuclide therapy (PRRT) to treat solid tumor cancers.

The process is considered safe and has shown to be effective in many different types of cancers including renal cell carcinoma, leukemia, and Hodgkin's disease. Although this type of therapy has a very high success rate, there are some limitations to the procedure that must be considered before undergoing it. When it comes to geographical impact, North America seems to be gaining significant traction in the peptide receptor radionuclide therapy (PRRT) market. This is due to growing product approval by drug regulatory authorities such as the U.S. Food and Drug Administration (FDA) in the U.S. On the contrary, Asia Pacific is registering a positive outlook, which is attributed to rising incidence of neuroendocrine tumors in the region.

Unfortunately, even with the benefits of PRRT initiation, there are still some limitations. One of the most common ways to implement part is to begin at a higher dose and to continue it until the patient is experiencing a significant deterioration in his or her condition. However, there are various challenges that could potentially limit growth of the said market in the near future. For instance, high cost associated with cancer that includes diagnosis and therapeutic treatment could impede growth of the peptide receptor radionuclide therapy (PRRT) market.